8 years ago

Medherant Secures £3.8 Million to Advance Transdermal Patch Technology

  • Medherant, a UK-based company developing innovative transdermal drug delivery patch technology, has raised £3.8 million in funding led by existing investor Mercia Technologies PLC

  • The funds will be used to move into clinical development and commercialize the company's ibuprofen TEPI Patch®, as well as initiate development of its lidocaine TEPI Patch®.

      • ProblemHealthcare

      "making it easier for patients to manage pain with transdermal drug delivery patches"

      Solution

      "developing an innovative transdermal drug delivery patch technology called TEPI Patch® to deliver higher doses of drugs through the skin"

      Covered on